What Happened
- A study published in Lancet Oncology, led by researchers from the Institute for Health Metrics and Evaluation (IHME), University of Washington, found that India recorded approximately 2.03 lakh breast cancer cases in 2023 — nearly a 477% increase since 1990.
- Deaths from breast cancer in India also rose sharply, with over one lakh deaths recorded in 2023 — a 352.3% increase since 1990.
- Globally, the study projects breast cancer cases will rise to 3.5 million by 2050, up from 2.3 million in 2023 — a 44% increase — with deaths rising 44% to approximately 1.37 million annually.
- The increasing burden is shifting disproportionately to low- and lower-middle-income countries (LMICs), where late-stage diagnosis, limited access to quality care, and higher mortality rates prevail.
- India's steep increase reflects a combination of factors: a rapidly ageing population, urbanisation, changing lifestyle patterns (diet, physical activity, reproductive behaviours), and improved reporting and detection in recent decades.
- The findings underscore urgent gaps in India's cancer screening infrastructure, early detection capacity, and accessible treatment facilities.
Static Topic Bridges
India's Cancer Burden and the National Cancer Control Framework
India's cancer burden has been growing for decades, driven by both communicable (infection-related) and non-communicable disease pathways. Breast cancer is now the leading cancer among Indian women by incidence, overtaking cervical cancer. India's primary national framework for addressing cancer is the National Programme for Non-Communicable Diseases (NP-NCD), which covers cancer, diabetes, cardiovascular disease, and stroke. For cancer specifically, the National Cancer Grid (NCG) — a network of 260+ institutions established by the Department of Atomic Energy (Tata Memorial Centre, Mumbai leads) — aims to standardise cancer care and research across the country.
- National Cancer Grid (NCG): 260+ member institutions; provides uniform protocols for cancer diagnosis and treatment; operates under the Department of Atomic Energy's cancer mandate (Tata Memorial Centre).
- Ayushman Bharat–PM-JAY: Covers cancer treatment up to ₹5 lakh per family per year; however, coverage gaps for expensive targeted therapies remain.
- National Registry of Cancer: India's hospital-based and population-based cancer registries (PBCR) under the Indian Council of Medical Research (ICMR) track incidence, mortality, and survival data — basis for policy planning.
- Cervical cancer vs breast cancer: Cervical cancer was historically the leading female cancer in India (linked to HPV infection); breast cancer has now overtaken it in urban India, while cervical cancer remains higher in rural areas.
- HER2-positive breast cancer: A common subtype in India; targeted drugs like trastuzumab (Herceptin) are expensive; biosimilar versions approved in India reduce cost but access remains uneven.
Connection to this news: The 477% rise reported in the Lancet study makes the adequacy of India's cancer infrastructure — NCG coverage, PM-JAY limits, ICMR registry completeness — an urgent policy question.
Risk Factors and the Epidemiological Transition in India
The surge in breast cancer reflects India's ongoing epidemiological transition — the shift from communicable to non-communicable diseases as economic development proceeds. Established breast cancer risk factors include: late age at first childbirth (>30 years), fewer pregnancies, shorter duration or no breastfeeding, early menarche, late menopause, obesity (especially post-menopausal), alcohol consumption, hormonal contraceptive use, and inherited gene mutations (BRCA1/BRCA2). Urban Indian women are increasingly experiencing several of these risk factors simultaneously due to changing social and reproductive norms.
- BRCA1 and BRCA2 mutations: Inherited gene mutations that significantly increase lifetime risk of breast (and ovarian) cancer; account for ~5-10% of all breast cancer cases globally; genetic testing adoption in India is growing but remains limited.
- Menarche age in India has dropped from ~13.7 years (1970s) to ~12.5 years (recent data) — an established risk factor increase.
- Urbanisation and breast cancer: Urban Indian women have breast cancer incidence ~2-3 times higher than rural women, reflecting lifestyle and reproductive pattern differences.
- Obesity: India has one of the world's fastest-growing obesity rates; post-menopausal obesity is one of the most modifiable breast cancer risk factors.
- WHO Global Breast Cancer Initiative (GBCI, 2021): Aims to reduce global breast cancer mortality by 2.5% annually; pillars are health promotion, early detection, and access to diagnosis and treatment.
Connection to this news: The epidemiological transition context explains why a large-population developing country like India is seeing faster growth in breast cancer incidence than high-income countries — making lifestyle-focused preventive interventions increasingly urgent.
Screening, Early Detection, and Healthcare Equity
Survival rates for breast cancer are strongly correlated with stage at diagnosis: 5-year survival rates exceed 90% for Stage I but drop below 30% for Stage IV. In high-income countries, population-based mammographic screening has successfully shifted diagnosis toward earlier stages. In India, the absence of a national breast cancer screening program means that ~60% of cases are diagnosed at Stages III or IV — when treatment is costly, complex, and survival rates much lower. The Lancet study's finding that mortality is growing fastest in LMICs is directly linked to this diagnostic delay.
- Mammography screening guidelines: Recommended every 1-2 years for women aged 40-74 in high-income countries; no equivalent national program in India yet.
- Clinical breast examination (CBE): A lower-cost alternative recommended by WHO for LMICs; the National Urban Health Mission has trained ASHA workers for CBE, but coverage is inconsistent.
- Stage at diagnosis in India: ~60% present at Stage III/IV (late stage) vs ~25% in the US — a key metric of screening program effectiveness.
- Tele-oncology: ISRO's telemedicine network and NCI's telemedicine links have been used to extend oncology consultation to rural India, but pathology capacity remains a bottleneck.
- Sustainable Development Goal 3.4: Aims to reduce premature mortality from non-communicable diseases by one-third by 2030 — breast cancer trajectory in India is a direct concern for this target.
Connection to this news: The 477% increase in cases and 352% increase in deaths since 1990 demands a policy response that addresses not just treatment capacity but the earlier stages of the care pathway — screening, awareness, and timely diagnosis at primary and secondary health levels.
Key Facts & Data
- Lancet Oncology study: Led by IHME, University of Washington; based on Global Burden of Disease data.
- India breast cancer incidence (2023): ~2.03 lakh cases — 477% increase since 1990.
- India breast cancer deaths (2023): >1 lakh — 352.3% increase since 1990.
- Global projection: 3.5 million cases by 2050 (from 2.3 million in 2023); deaths up 44% to ~1.37 million/year.
- Breast cancer is now the leading cancer among Indian women by incidence.
- ~60% of Indian breast cancer cases diagnosed at Stage III or IV.
- 5-year survival: >90% (Stage I) vs <30% (Stage IV).
- BRCA1/BRCA2 mutations: account for ~5-10% of breast cancer cases globally.
- National Cancer Grid (NCG): 260+ institutions; led by Tata Memorial Centre under Department of Atomic Energy.
- PM-JAY: Covers cancer treatment up to ₹5 lakh per family per year.
- SDG 3.4: Reduce premature NCD mortality by one-third by 2030.